At present, Biotechnology is quickly changing, from an industry of research and development, to an industry of manufacturing, sales and marketing. Five increasingly developing fields can be mentioned: stem cell use, production of DNA chips and proteins, clinical nanotechnology, tissue engineering and proteomic development.
Biocell Ultravital's bioresearch institute, with more than 70 years devoted to the research and development of specific high-power biomaterial vital for the human body, continues to develop new therapies in which we have succeeded in having the dysfunctional cells of the recipient regenerate for their repair and revitalization within the strictest and most rigorous controls exacted by bio-safety. For the most part, we employ natural substances so-called cell compounds using extracts of animal and plant origin that are 100% safe true bio-medications for cell nutrition that progressively induce the repair and normalization of the cell cycle as a curing mechanism. When what is used is the injection of whole cells, we are speaking of cell renewal.
The success of our cell treatments lies mainly in the fact that they are accepted by the recipient body without risk of rejection or possible disorders in the cell genetics of the recipient; its effects are revitalizing in a first phase and regenerative subsequently. Of course, they do not produce the therapeutic effect response known by all; rather, to the contrary, it is the body that modifies itself. Unlike chemical drugs, that can alter the rhythm of the existing biological processes (e.g., chemotherapy), our products lack the capacity to impose themselves on the target organ; rather, they only act to the extent that they are accepted and incorporated as integral, wherefore they can never act by injuring the recipient body. The subsequent reactions over time (for example, the sustained increase in production of a hormone) are not due to the residual action, but to the biological response on the part of the recipient. The very complex but at the same time simple composition of our products, although it may sound contradictory, is the farthest thing from the simplicity of the mono-drug, which pharmacology seeks as an efficacious substance. Whereas it focuses generally on symptomatology, classic therapeutics is geared towards the final links of the disease; that is, it is more symptomatic than causal, and is aimed pathogenetically and therapeutically towards the consequences and not towards whether the fault is due to the level of the mitochondria, ribosomes or cytomembranes, misdirected or misprogrammed genetically, in simple words, to cell disorders.
In natural fashion, the body's tissues throughout one's lifetime suffer wear, from which they defend themselves by developing the intrinsic capacity to self-renew those tissues that become worn. Should this type of self-renewal not exist, the life expectancy of living being would be considerably reduced.
All living beings are made up by cells and all the body's cells have exactly the same genetic information.
However, not all of them behave the same. We know that regulation of growth and cell division (cell cycle) is very complex. In the cell cycle there are points of restriction that impede the normal continuation of the cycle for various reasons, such as, for example, if the cells have not attained sufficient size, lack nutrients, the DNA is damaged or receives outside chemical damage, etc.
Normal development is a balanced process which includes cell proliferation and death. The processes of cell proliferation and death by apoptosis are even more complex and involve the participation of many genes. In both processes, suppressor gene p53 is one of the most important and studied genes or protein. This transcription factor activates a variety of genes, resulting in the inhibition of the progression of the cell cycle and cell repair, or in apoptosis. The signals that activate p53 function include damage to the DNA that takes part in the inhibition of cell cycle progression during phase G1.
When a cell is damaged, the cycle's being detained or apoptosis's being induced depends on the intensity of the damage. The final result of the different mechanisms of action of p53 is to maintain the genomic stability of the cells. Therefore, the deficiency of this protein contributes to genomic instability, to the accumulation of mutations and the acceleration of tumourigenesis; p53 is mutated in 50-55 percent of all types of cancer in humans.
These mutations are localized mainly in the domain of union to DNA, which results in the loss of its biological activity.
As you may note, the previous example is just one case that refers to cell disorders that lead to often incurable diseases, but there are many factors that can unleash disorders in normal and sound cell development. However, what is proven is that these are due to one or more deficiencies in elemental cell function and/or deterioration in its own environment.
On the other hand, the broad roster of diseases that affect the human body are based on cell degeneration and the consequent death of the different tissues that make up our bodies, whether acutely (infarctions) or chronically (degeneration- ageing).It is for this reason that we have included in our tissues embryonic cell precursor tissues which correspond to the formulas of 2nd generation cell and precursor tissue products with a rich content of pluripotent cells, as is the unique case of the HUMAN ULTRACELL 3 G product. In this way, we succeeded in making available to the human body new cell materials which will give a new dynamic to previous formulas of our already recognized products and we are especially giving it a new therapeutic potential with the sufficient difference of ensuring optimum cell function which distances the body for as long as possible from the cell damage which will inevitably become pathologies and diseases with a greater influence on all ageing processes.
The use of these new components in our formulas conditions major achievements for regenerative and anti-ageing medicine through our products.